Combotope Therapeutics has entered into a strategic research collaboration with Boehringer Ingelheim to develop a new generation of tumor-selective antibody therapies for cancer. The partnership will combine Combotope’s proprietary antibody discovery technology with Boehringer Ingelheim’s expertise in oncology drug development to identify promising treatments for cancers that have few targeted therapy options.
Under the agreement, the companies will work together on multiple oncology targets initially selected by Boehringer Ingelheim, with the possibility of expanding the collaboration to additional targets in the future. The financial terms of the deal were not disclosed, although Combotope will receive an upfront payment, research funding for each target, milestone payments tied to development and commercialization, and royalties on future product sales.
The collaboration centers on Combotope’s SMART-Phage™ platform, a technology designed to discover antibodies that recognize highly specific markers found primarily on cancer cells. Unlike conventional antibody discovery approaches that typically target proteins alone, Combotope focuses on unique combinations of sugars and proteins, known as glycan-protein epitopes, or “combotopes.”
These glycan-protein markers, including structures such as Tn and STn, are found at much higher levels on tumor cells than on healthy tissue. Because they serve as more precise biological signatures of cancer, researchers believe they could enable the development of antibody therapies that more accurately distinguish cancer cells from normal cells, potentially improving treatment effectiveness while reducing damage to healthy tissue.
The approach could be particularly valuable for difficult-to-treat cancers where existing targeted therapies remain limited. By identifying highly selective cancer markers, the technology may also expand opportunities for developing advanced treatment approaches such as antibody-drug conjugates (ADCs), which deliver cancer-killing drugs directly to tumor cells while minimizing exposure to healthy tissues.
As part of the partnership, Combotope will use its SMART-Phage platform to generate high-affinity antibodies against the selected cancer targets. The company will also provide detailed characterization data for each antibody candidate before transferring the programs to Boehringer Ingelheim.
Boehringer Ingelheim will then take responsibility for advancing the candidates through preclinical research, clinical development, manufacturing, regulatory approval, and global commercialization. The pharmaceutical company will retain worldwide rights to any therapies resulting from the collaboration.
Combotope Chief Executive Officer Ola Blixt said the company’s technology is designed to address cancer-specific glycan-protein targets that have been difficult to target using traditional antibody discovery methods. By combining recognition of both sugar and protein structures, he said the platform has the potential to create a new class of highly tumor-selective antibodies and expand the number of viable targets available for cancer drug development.
The agreement represents another example of large pharmaceutical companies partnering with biotechnology firms that specialize in innovative discovery platforms. As interest in precision oncology continues to grow, collaborations focused on identifying more selective cancer targets are becoming increasingly important in the search for safer and more effective treatments.
For Combotope, the partnership provides both financial support and validation of its antibody discovery platform. For Boehringer Ingelheim, it offers access to an innovative technology that could strengthen its oncology pipeline with therapies targeting cancers that have historically been difficult to treat. If successful, the collaboration could pave the way for new precision medicines capable of reaching patients with cancers that currently have limited treatment options.